基石金融(08112.HK):终止股份配售事项
格隆汇5月14日丨基石金融(08112.HK)公布,内容有关公司与潮商证券有限公司就根据一般授权配售最多1144.8万股将予发行的公司新股份订立日期为2021年4月30日的配售协议。
由于配售协议所载完成配售事项的若干先决条件于2021年5月14日(即配售协议日期后第14天当日)或之前尚未达成,配售协议已于2021年5月14日失效,配售事项将不会进行。根据配售协议,公司于配售事项下之责任及负债将告失效,及公司根据配售事项之所有权利及责任将予以解除(惟(i)公司支付所有因该终止已产生或将产生的费用及开支;及(ii)任何先前的违反行为除外)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.